ERBB2 and neoplasm: The more potent rexinoid LG100268 and a SERM were highly effective at delaying tumor development in a similar murine model of HER2 + breast cancer, while the combination of a SERM and LG100268 completely prevented tumor development over a 50 week period of treatment20.